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ABSTRACT
The antimicrobial susceptibility patterns of 9322 contemporary (2002–2004) Gram-positive bacterial
isolates collected from 31 medical centres in 14 countries in Europe were evaluated by broth
microdilution methods according to CLSI guidelines. The isolates collected comprised Staphylococcus
aureus (4842 isolates), coagulase-negative staphylococci (CoNS; 1942 isolates), Enterococcus faecalis (1147
isolates), Enterococcus faecium (391 isolates), b-haemolytic streptococci (660 isolates) and viridans group
streptococci (340 isolates). The organisms were tested against daptomycin and more than 20 comparator
agents in Mueller–Hinton broth, supplemented with calcium to 50 mg ⁄L when testing daptomycin.
Overall, methicillin (oxacillin) resistance rates were 26.7% and 77.0% for S. aureus (MRSA) and CoNS,
respectively, and the vancomycin resistance rate among enterococci was 6.1%. MRSA rates varied from
0.6% in Sweden to 40.2–43.0% in Belgium, Greece, Ireland, the UK and Israel, and VRE rates varied
from 0% in Switzerland to 21.2% in Ireland. More than 99.9% of isolates tested were considered
susceptible to daptomycin according to breakpoints established by the United States Food and Drug
Administration and the CLSI. Daptomycin was active against all Gram-positive species, with the highest
MIC being 2, 8, 0.5 and 2 mg ⁄L for staphylococci, enterococci, b-haemolytic streptococci and viridans
group streptococci, respectively. Daptomycin activity was not influenced adversely by resistance to
other agents among staphylococci or enterococci. This novel lipopeptide (daptomycin) appears to be an
excellent alternative therapeutic option for serious infections caused by multidrug-resistant Gram-
positive organisms isolated in Europe.
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INTRODUCTION
The antimicrobial susceptibility patterns of bac-
teria isolated from hospitalised patients varies
significantly throughout Europe. Several surveil-
lance programmes, including the European Anti-
microbial Surveillance System (EARSS) and the
SENTRY antimicrobial surveillance programme,
routinely collect antimicrobial susceptibility data
in Europe [1,2]. These surveillance programmes
have revealed remarkable geographical variations
in a north–south gradient, with generally lower
resistance rates in northern Europe and higher
resistance rates in southern and western Europe
[1]. This trend is particularly evident for methi-
cillin (oxacillin)-resistant Staphylococcus aureus
(MRSA) [3]. With the increasing occurrence of
vancomycin-resistant enterococci (VRE) and the
emergence of Staph. aureus strains with decreased
susceptibility to vancomycin, antimicrobial
agents with activity focused against Gram-posi-
tive cocci are required for therapy of infections
caused by these multidrug-resistant (MDR)
strains [4–6].
Daptomycin is a naturally occurring cyclic
lipopeptide produced by Streptomyces roseosporus,
and has shown activity against most Gram-posi-
tive bacterial species [7,8]. This compound joins
other newer agents active against Gram-positive
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bacteria, including quinupristin–dalfopristin (a
streptogramin combination) and linezolid (an
oxazolindinone), in their ability to treat contem-
porary MDR Gram-positive infections. A once-
daily dosing regimen, with minimal side-effects,
makes daptomycin a promising alternative for the
treatment of nosocomial infections caused by
Gram-positive organisms [7,9,10]. Daptomycin is
active against a wide range of MDR strains for
which there are few therapeutic alternatives,
including VRE, MRSA, vancomycin-intermediate
Staph. aureus and penicillin-resistant streptococci
[11].
Daptomycin has been approved by the United
States Food and Drug Administration (US-FDA)
for the treatment of complicated skin and skin-
structure infections at a dose of 4 mg ⁄ kg every
24 h. Daptomycin has a rapid bactericidal effect,
and a supplemental filing has been submitted to
the US-FDA for the treatment of Staph. aureus
bacteraemia and infectious endocarditis at a dose
of 6 mg ⁄kg every 24 h [12]. Despite the absence of
studies in humans, daptomycin has also been
used successfully to treat osteomyelitis, with
minimal adverse events and a low potential for
the development of drug resistance [13,14]. How-
ever, daptomycin is not indicated for treatment of
pneumonia, because of its inhibition by pulmon-
ary surfactants [15].
Daptomycin has recently been approved for the
treatment of complicated skin and skin-structure
infections in Europe. Thus, it is important to
review the antimicrobial susceptibility of Gram-
positive pathogens isolated in European hospitals
during recent years in order to evaluate the
necessity for this new compound, as well as the
potency and spectrum of daptomycin against
isolates from different European countries. The
present study evaluated the antimicrobial suscep-
tibility patterns of contemporary (2002–2004)
clinical isolates of Gram-positive bacteria collect-
ed from Europe and the Middle East.
MATERIALS AND METHODS
Bacterial isolates
The Daptomycin Surveillance Programme was established in
2002 with the objective of monitoring the in-vitro activity of
daptomycin and most antimicrobial agents used to treat
infections caused by Gram-positive organisms. The pro-
gramme collected Gram-positive bacterial isolates from
documented clinical infections, mainly complicated skin and
skin-structure infections and bloodstream infections. The
isolates were collected in 31 medical centres located in Europe
(14 countries) and 31 centres in North America (these isolates
are not reported here), according to a common protocol [2], as
commercial susceptibility systems used routinely do not test
daptomycin. The European medical centres were located in
Belgium (one), France (six), Germany (five), Greece (one),
Ireland (one), Israel (one), Italy (three), Poland (one), Russia
(one), Spain (three), Sweden (two), Switzerland (one), Turkey
(two) and the UK (three). All isolates were identified locally
and forwarded to a central monitoring laboratory (JMI Labor-
atories, North Liberty, IA, USA) for confirmation of species
identification, when necessary, and reference susceptibility
testing.
Susceptibility testing
The isolates were tested using CLSI broth microdilution
methods [16]. Daptomycin and more than 20 comparator
agents were tested in validated, dry-form microdilution
panels manufactured by TREK Diagnostics Systems (Cleve-
land, OH, USA). The test medium was Mueller–Hinton
broth, adjusted to contain physiological levels of calcium
(50 mg ⁄L) when testing daptomycin [16,17]. The isolates
were categorised as susceptible, intermediately-resistant or
resistant according to CLSI interpretive criteria [17]. A
daptomycin susceptibility breakpoint of £1 mg ⁄L was used
for staphylococci and b-haemolytic streptococci, while
£4 mg ⁄L was used for interpretation of enterococci, as
approved by the US-FDA [11] and CLSI [17]. Streptococcus
pneumoniae ATCC 49619, Enterococcus faecalis ATCC 29212
and Staph. aureus ATCC 29213 were tested concurrently as
quality control organisms. More recently, the European
Committee for Antimicrobial Susceptibility Testing (EUCAST)
has recommended daptomycin-susceptible and -resistant
breakpoints of £1 mg ⁄L and ‡2 mg ⁄L, respectively, for
staphylococci and streptococci only [18].
RESULTS
In total, 9322 non-duplicate Gram-positive cocci
were evaluated in the present study. The collec-
tion comprised Staph. aureus (4842 isolates),
coagulase-negative staphylococci (CoNS; 1942
isolates), E. faecalis (1147 isolates), Enterococcus
faecium (391 isolates), b-haemolytic streptococci
(660 isolates), and viridans group streptococci
(340 isolates). The antimicrobial susceptibility
patterns of these isolates are summarised in
Table 1. Overall, daptomycin and linezolid were
the most active compounds tested. The highest
daptomycin MICs were 2, 8, 0.5 and 2 mg ⁄L for
staphylococci, enterococci, b-haemolytic strepto-
cocci and viridans group streptococci, respect-
ively. More than 99.9% of the non-enterococcal
isolates tested were inhibited by daptomycin at
£1 mg ⁄L (0.12% non-susceptible), and all but two
enterococcal isolates (also 0.12%) were inhibited
at £4 mg ⁄L.
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Table 1. Antimicrobial susceptibility patterns of Gram-positive bacterial isolates collected from European hospitals during
2002–2004 (9322 isolates)
Organism/antimicrobial agent (no. tested)
MIC (mg/L) % by category
50% 90% Range Susceptiblea Resistanta
Staphylococcus aureus
Oxacillin-susceptible (3550)
Daptomycin 0.25 0.5 £0.06–2 >99.9 –
Erythromycin 0.25 >8 £0.06 to >8 84.8 14.1
Clindamycin 0.12 0.12 £0.06 to >8 96.9 2.8
Ciprofloxacin 0.25 0.5 £0.03 to >4 92.8 6.1
Levofloxacin 0.12 0.25 £0.03 to >4 94.1 5.5
Tetracycline £4 £4 £4 to >8 93.7 5.8
Trimethoprim–sulphamethoxazole £0.5 £0.5 £0.5 to >2 99.1 0.9
Quinupristin–dalfopristin £0.25 0.5 £0.25 to >2 99.9 0.1
Teicoplanin £2 £2 £2–4 100.0 0.0
Vancomycin 1 1 £0.12–4 >99.9 0.0
Linezolid 2 2 0.12–8 >99.9 –
Oxacillin-resistant (1292)
Daptomycin 0.25 0.5 £0.12–2 99.9 –
Erythromycin >8 >8 0.12 to >8 24.9 74.1
Clindamycin 0.25 >8 £0.06 to >8 50.9 49.0
Ciprofloxacin >4 >4 0.06 to >4 9.2 90.4
Levofloxacin >4 >4 0.06 to >4 9.4 86.8
Tetracycline £2 >8 £2 to >8 74.9 23.4
Trimethoprim–sulphamethoxazole £0.5 1 £0.5 to >2 93.2 6.8
Quinupristin–dalfopristin 0.5 1 0.12 to >8 98.8 0.9
Teicoplanin £2 £2 £2–16 99.8 0.0
Vancomycin 1 1 0.25–2 100.0 0.0
Linezolid 2 2 0.25–2 100.0 –
Coagulase-negative staphylococci
Oxacillin-susceptible (447)b
Daptomycin 0.25 0.5 0.06–1 100.0 –
Erythromycin 0.25 >8 £0.06 to >8 71.8 28.0
Clindamycin £0.06 0.12 £0.06 to >8 95.5 3.8
Ciprofloxacin 0.25 1 £0.03 to >4 90.4 8.7
Levofloxacin 0.25 0.5 £0.03 to >4 90.8 7.8
Tetracycline £2 >8 £2 to >8 83.4 16.2
Trimethoprim–sulphamethoxazole £0.5 >2 £0.5 to >2 89.0 11.0
Quinupristin–dalfopristin £0.25 £0.25 £0.25–1 100.0 0.0
Teicoplanin £2 4 £2–16 97.3 0.0
Vancomycin 1 2 0.25–4 100.0 0.0
Linezolid 1 1 £0.25–2 100.0 –
Oxacillin-resistant (1495)c
Daptomycin 0.25 0.5 £0.06–1 100.0 –
Erythromycin >8 >8 £0.06 to >8 29.0 70.5
Clindamycin 0.12 >8 £0.06 to >8 62.9 36.6
Ciprofloxacin >4 >4 0.06 to >4 30.8 63.9
Levofloxacin 4 >4 0.06 to >4 32.2 58.7
Tetracycline £2 >8 £2 to >8 82.0 17.4
Trimethoprim–sulphamethoxazole 2 >2 £0.5 to >2 50.9 49.1
Quinupristin–dalfopristin £0.25 0.5 £0.25 to >8 99.2 0.5
Teicoplanin £2 8 £2 to >16 97.0 0.6
Vancomycin 1 2 £0.12–4 100.0 0.0
Linezolid 1 1 0.25–2 100.0 –
Enterococcus faecalis
Vancomycin-susceptible (1113)
Daptomycin 0.5 1 £0.06–4 100.0 –
Ampicillin 2 4 £1 to >16 99.1 0.9
Gentamicin (high-level) £500 >1000 £500 to >1000 72.3 27.7
Streptomycin (high-level) £1000 >2000 £1000 to >2000 65.5 34.5
Levofloxacin 1 >4 0.06 to >4 71.4 27.6
Chloramphenicol 8 >16 £2 to >16 73.8 25.7
Quinupristin–dalfopristin >2 >2 £0.25 to >2 1.9 91.3
Teicoplanin £2 £2 £2–4 100.0 0.0
Linezolid 2 2 0.5–4 99.9 0.0
Vancomycin-resistant (34)
Daptomycin 0.5 1 0.25–2 100.0 –
Ampicillin 2 4 £1–8 100.0 0.0
Gentamicin (high-level) >1000 >1000 £500 to >1000 27.6 72.4
Streptomycin (high-level) >2000 >2000 £1000 to >2000 27.6 72.4
Levofloxacin >4 >4 0.5 to >4 23.5 76.5
Chloramphenicol 8 >16 4 to >16 85.3 14.7
Quinupristin–dalfopristin >2 >2 >2 0 100.0
Teicoplanin >16 >16 £0.12 to >16 17.6 79.4
Linezolid 1 2 0.5–2 100.0 0.0
Enterococcus faecium
Vancomycin-susceptible (322)
Daptomycin 2 4 £0.06–8 99.7 –
Ampicillin >16 >16 £1 to >16 17.8 82.2
Gentamicin (high-level) £500 >1000 £500 to >1000 71.8 28.2
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Staphylococci
Overall oxacillin resistance rates for Europe were
26.7% and 77.0% for Staph. aureus and CoNS,
respectively (Table 1). However, some countries
had resistance rates >40% for Staph. aureus (Bel-
gium, Greece, Ireland, Israel and the UK) and
>85% for CoNS (Ireland, Israel, Poland, Russia
and Turkey). The highest oxacillin susceptibility
rates for Staph. aureus were observed in Sweden
(99.4%), where the lowest susceptibility rate for
any of the study agents was 94.5% (ciprofloxacin
and erythromycin; Table 2). Only one Staph. au-
reus and one CoNS isolate with decreased sus-
ceptibility to teicoplanin were detected, both from
Poland. MRSA isolates demonstrated high rates
of co-resistance to erythromycin (24.9% suscept-
ible), ciprofloxacin (9.2% susceptible) and levo-
floxacin (9.4% susceptible); however, resistance to
oxacillin did not influence daptomycin activity
adversely.
All Staph. aureus isolates were susceptible to
daptomycin (MIC90 0.5 mg ⁄L), except two iso-
lates with daptomycin MICs of 2 mg ⁄L, isolated
in France and Switzerland. All CoNS isolates
were susceptible to daptomycin. Vancomycin
(MIC90 1 mg ⁄L) was active against all but one of
the 6784 staphylococcal isolates at the current
CLSI susceptible breakpoint of £2 mg ⁄L. Linezo-
lid, teicoplanin and quinupristin–dalfopristin
were also highly active against staphylococci,
with susceptibility rates of ‡99.8%.
Daptomycin was the most potent compound
against MRSA (lowest MIC50 and MIC90 values;
Table 1). There were no significant variations in
the daptomycin potency against staphylococci
Table 1. Continued
Organism/antimicrobial agent (no. tested)
MIC (mg/L) % by category
50% 90% Range Susceptiblea Resistanta
Streptomycin (high-level) £1000 >2000 £1000 to >2000 52.6 47.4
Levofloxacin >4 >4 0.5 to >4 26.1 63.4
Chloramphenicol 8 16 £2 to >16 75.7 8.4
Quinupristin–dalfopristin 1 2 £0.25 to >2 70.8 8.4
Teicoplanin £2 £2 £2 100.0 0.0
Linezolid 2 2 £0.25–2 100.0 0.0
Vancomycin-resistant (69)
Daptomycin 2 4 0.5–8 98.6 –
Ampicillin >16 >16 £1 to >16 4.6 95.4
Gentamicin (high-level) £500 >1000 £500 to >1000 54.5 45.5
Streptomycin (high-level) £1000 >2000 £1000 to >2000 52.7 47.3
Levofloxacin >4 >4 1 to >4 15.9 81.2
Chloramphenicol 8 16 4 to >16 72.5 7.2
Quinupristin–dalfopristin 0.5 2 £0.25 to >2 84.1 8.7
Teicoplanin >16 >16 0.25 to >16 17.4 71.0
Linezolid 2 2 1–2 100.0 0.0
b-Haemolytic streptococci (660)d
Daptomycin £0.06 0.25 £0.06–0.5 100.0 –
Penicillin £0.016 0.06 £0.016–0.12 100.0 –
Erythromycin £0.06 4 £0.06 to >32 84.1 15.6
Clindamycin £0.06 £0.06 £0.06 to >8 94.2 5.2
Tetracycline £2 >8 £2 to >8 51.5 41.1
Levofloxacin 0.5 1 0.06 to >4 99.5 0.3
Vancomycin 0.25 0.5 £0.12–1 100.0 –
Linezolid 1 1 0.06–2 100.0 0.3
Viridans group streptococci (340)e
Daptomycin 0.25 0.5 0.03–2 99.1 –
Penicillin 0.06 2 £0.016 to >32 72.9 7.9
Erythromycin £0.06 >8 £0.06 to >8 58.5 36.5
Clindamycin £0.06 >8 £0.06 to >8 84.1 14.1
Levofloxacin 1 1 £0.03 to >4 98.2 1.8
Vancomycin 0.5 1 £0.12–1 100.0 –
Linezolid 1 1 0.06–2 100.0 –
aAccording to CLSI criteria [17]; b-lactam susceptibility should be directed by the oxacillin test results.
bIncludes: Staphylococcus auricularis (4), Staphylococcus capitis (24), coagulase-negative staphylococci (CoNS) (110), Staphylococcus epidermidis (228), Staphylococcus haemolyticus
(13), Staphylococcus hominis (29), Staphylococcus intermedius (2), Staphylococcus lugdunensis (3), Staphylococcus saprophyticus (2), Staphylococcus schleiferi (2), Staphylococcus simulans
(3), Staphylococcus spp. (4), Staphylococcus warnerii (15) and Staphylococcus xylosis (8).
cIncludes: Staph. auricularis (4), Staph. capitis (18), Staphylococcus chromogenes (1), CoNS (328), Staphylococcus cohnii (3), Staph. epidermidis (858), Staph. haemolyticus (107),
Staph. hominis (54), Staph. intermedius (5), Staph. lugdunensis (18), Staph. saprophyticus (27), Staphylococcus sciuri (1), Staph. simulans (16), Staphylococcus spp. (8), Staph. warnerii
(23) and Staph. xylosis (24).
dIncludes: b-haemolytic streptococci (14), Streptococcus dysgalactiae (13), Streptococcus equi (2), Streptococcus equisimilis (5), group A streptococci (334), group B streptococci (190),
group C streptococci (21), group F streptococci (2) and group G streptococci (79).
eIncludes: Streptococcus acidominimus (2), a-haemolytic streptococci (9), Streptococcus anginosus (39), Streptococcus bovis (21), Streptococcus constellatus (26), Streptococcus equinus
(1), Streptococcus gallolyticus (2), Streptococcus gordonii (6), Streptococcus intermedius (11), Streptococcus milleri (11), Streptococcus mitis (65), Streptococcus mutans (8), Streptococcus
oralis (40), Streptococcus parasanguis (5), Streptococcus salivarius (19), Streptococcus sanguis (24), Streptococcus spp. (23), Streptococcus vestibularis (1) and Streptococcus viridans (27).
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among the countries evaluated, with 98.2–100%
of isolates being inhibited by daptomycin
£0.5 mg ⁄L (Table 3), or over time (data not
shown).
Enterococci
The overall rate of vancomycin resistance was
6.7%, and VRE isolates also showed increased
rates of high-level resistance to gentamicin (45.5–
72.4%; Table 1). Daptomycin was the most potent
agent (MIC90 1 mg ⁄L) and was the only com-
pound active against all E. faecalis isolates at
the current susceptible breakpoint (Table 1).
Ampicillin (MIC90 4 mg ⁄L) and linezolid
(MIC90 2 mg ⁄L) were active against all vancomy-
cin-resistant E. faecalis isolates. Two E. faecium
isolates were non-susceptible to daptomycin, both
with MICs of 8 mg ⁄L (susceptible at £4 mg ⁄L
[17]). Linezolid and daptomycin were the only
agents with significant activity (>99% suscepti-
bility) against E. faecium.
Table 2. Antimicrobial spectrum of antimicrobial agents used to treat Gram-positive infections, grouped by country
Organism/antimicrobial agent
% susceptible
Belgium France Germany Greece Ireland Israel Italy Poland Russia Spain Sweden Switzerland Turkey UK
Staphylococcus aureus (no. tested) (100) (1100) (715) (128) (328) (121) (386) (242) (69) (317) (325) (189) (291) (531)
Daptomycin 100.0 99.9 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.5 100.0 100.0
Oxacillin 59.0 71.5 90.2 59.4 59.8 57.0 64.8 67.8 66.7 82.0 99.4 81.5 73.2 58.0
Erythromycin 48.0 69.3 75.8 75.0 57.0 64.5 57.3 69.0 53.6 75.7 94.5 78.8 69.1 56.5
Clindamycin 73.0 81.9 89.7 79.7 92.1 78.5 72.3 77.3 68.1 96.5 97.2 87.8 85.2 81.9
Ciprofloxacin 58.0 70.2 77.6 68.8 57.6 56.2 62.7 71.7 75.4 78.5 94.5 76.2 73.9 56.7
Levofloxacin 62.0 71.5 78.3 71.1 58.2 56.2 63.0 72.7 75.4 79.8 96.9 77.2 74.2 56.9
Tetracycline 79.0 93.5 94.4 62.5 98.2 94.2 94.0 54.5 72.7 98.4 96.3 94.7 61.9 88.3
Trimethoprim–sulphamethoxazole 97.0 99.1 98.7 96.9 99.7 93.3 95.9 90.9 100.0 99.1 100.0 98.9 99.0 92.7
Quinupristin–dalfopristin 100.0 98.5 99.9 100.0 100.0 100.0 99.7 100.0 100.0 100.0 100.0 100.0 100.0 99.8
Linezolid 100.0 100.0 100.0 99.2 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Teicoplanin 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.2 100.0 100.0 100.0 100.0 100.0 100.0
Vancomycin 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.6 100.0 100.0 100.0 100.0 100.0 100.0
Coagulase-negative staphylococci
(no. tested)
(29) (379) (517) (57) (18) (76) (299) (29) (7) (129) (67) (107) (171) (62)
Daptomycin 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Oxacillin 17.2 22.9 31.5 19.3 11.1 5.3 15.4 13.8 14.3 26.4 36.9 24.3 14.0 25.8
Erythromycin 41.4 46.8 38.9 35.1 22.2 36.8 33.8 27.6 28.6 40.3 64.6 29.9 32.2 35.5
Clindamycin 65.5 79.0 66.0 50.9 77.8 68.4 66.6 55.2 71.4 81.4 67.7 72.0 68.4 85.5
Ciprofloxacin 44.8 46.0 44.1 56.1 50.0 46.1 37.5 55.2 42.9 49.6 56.9 37.4 39.2 58.1
Levofloxacin 44.8 47.1 44.7 59.6 50.0 46.1 39.5 55.2 42.9 49.6 60.0 36.4 40.9 64.5
Tetracycline 75.9 85.4 84.9 87.7 72.2 78.9 81.9 48.3 85.7 89.1 87.7 89.7 62.9 87.1
Trimethoprim–sulphamethoxazole 50.0 60.3 59.7 61.4 55.6 38.2 66.6 58.6 28.6 70.5 61.5 46.7 55.9 64.5
Quinupristin–dalfopristin 100.0 98.1 99.8 96.5 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 98.8 100.0
Linezolid 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Teicoplanin 96.6 97.6 96.9 98.2 94.4 97.4 100.0 96.6 100.0 97.7 96.9 99.1 98.8 98.4
Vancomycin 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Enterococcus spp. (no. tested) (48) (247) (353) (62) (80) (39) (166) (32) (23) (144) (131) (58) (134) (99)
Daptomycin 100.0 100.0 99.7 100.0 100.0 97.4 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Ampicillin 87.9 91.3 73.5 68.5 52.2 78.4 69.3 73.7 76.2 100.0 100.0 81.3 61.2 78.8
Gentamicin (high-level) 89.6 85.0 67.8 51.0 44.4 61.5 62.7 46.4 60.9 89.4 80.8 90.2 71.6 62.0
Levofloxacin 75.0 78.5 56.1 27.4 22.5 59.0 48.8 59.4 78.3 64.6 89.7 84.5 65.7 35.4
Chloramphenicol 85.4 70.0 79.3 93.5 61.3 63.2 70.5 62.5 47.8 73.6 61.8 77.6 68.7 76.8
Quinupristin–dalfopristin 18.8 10.5 19.5 32.3 41.3 17.9 23.5 21.9 26.1 6.9 89.3 15.5 40.3 21.2
Linezolid 100.0 99.6 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Teicoplanin 100.0 99.2 96.9 80.6 81.3 87.2 86.7 96.9 100.0 99.3 99.2 100.0 96.3 86.7
Vancomycin 95.8 98.4 95.8 80.6 78.8 84.6 84.3 96.9 91.3 98.6 96.9 100.0 96.3 84.8
b-Haemolytic streptococci
(no. tested)
(12) (169) (80) (3) (18) (18) (16) (9) (34) (60) (85) (31) (7) (118)
Daptomycin 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Penicillin 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Clindamycin 100.0 86.4 97.5 100.0 100.0 100.0 100.0 100.0 97.1 95.0 92.9 100.0 100.0 97.5
Erythromycin 100.0 76.8 91.3 100.0 94.4 88.9 50.0 88.9 85.3 65.0 90.6 100.0 85.7 89.8
Tetracycline 25.0 49.7 37.5 66.7 50.0 50.0 68.8 55.6 61.8 76.7 45.0 67.7 57.1 47.9
Linezolid 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Vancomycin 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Viridans group streptococci
(no. tested)
(22) (85) (45) (1) (4) (13) (6) (2) (0) (22) (48) (35) (26) (31)
Daptomycin 100.0 98.8 97.8 100.0 100.0 100.0 100.0 100.0 – 100.0 100.0 100.0 100.0 96.8
Penicillin 68.2 72.9 84.4 100.0 50.0 53.8 50.0 0.0 – 72.7 83.3 82.9 30.8 87.1
Clindamycin 72.7 78.8 93.3 100.0 100.0 92.3 50.0 100.0 – 63.6 93.8 91.4 73.1 93.5
Erythromycin 59.1 54.1 57.8 – 50.0 30.8 16.7 0.0 – 45.5 79.2 65.7 42.3 80.6
Linezolid 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 – 100.0 100.0 100.0 100.0 100.0
Vancomycin 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 – 100.0 100.0 100.0 100.0 100.0
848 Clinical Microbiology and Infection, Volume 12 Number 9, September 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 844–852
Table 3. Distribution of daptomycin MICs, grouped by country
Organism/country (no. tested)
No. of isolates (cumulative %) inhibited at MIC (mg/L):
£0.06 0.12 0.25 0.5 1 2 4 8
Staphylococcus aureus
Belgium (100) 5 (5.0) 69 (74.0) 26 (100.0)
France (1100) 47 (4.3) 750 (72.5) 297 (99.5) 5 (99.9) 1 (100.0)
Germany (715) 25 (3.5) 488 (71.7) 194 (98.9) 8 (100.0)
Greece (128) 6 (4.7) 88 (73.4) 33 (99.2) 1 (100.0)
Ireland (328) 11 (3.4) 227 (72.6) 89 (99.7) 1 (100.0)
Israel (121) 1 (0.8) 76 (63.6) 43 (99.2) 1 (100.0)
Italy (386) 22 (5.7) 200 (57.5) 151 (96.6) 13 (100.0)
Poland (242) 8 (3.3) 159 (69.0) 71 (98.3) 4 (100.0)
Russia (69) 3 (4.3) 56 (85.5) 10 (100.0)
Spain (317) 13 (4.1) 227 (75.7) 76 (99.7) 1 (100.0)
Sweden (325) 1 (0.3) 12 (4.0) 228 (74.2) 78 (98.2) 6 (100.0)
Switzerland (189) 9 (4.8) 119 (67.7) 54 (96.3) 6 (99.5) 1 (100.0)
Turkey (291) 1 (0.3) 10 (3.8) 180 (65.6) 99 (99.7) 1 (100.0)
UK (531) 13 (2.3) 361 (70.2) 154 (99.2) 4 (100.0)
Total (4842) 2 (0.0) 184 (3.8) 3228 (70.5) 1375 (98.9) 51 (>99.9) 2 (100.0)
Coagulase-negative staphylococci
Belgium (29) 3 (10.3) 22 (86.2) 4 (100.0)
France (376) 2 (0.5) 35 (9.8) 213 (66.5) 116 (97.3) 10 (100.0)
Germany (517) 4 (0.8) 39 (8.3) 262 (59.0) 190 (95.7) 22 (100.0)
Greece (57) 1 (1.8) 4 (8.8) 29 (59.6) 23 (100.0)
Ireland (18) 2 (11.1) 13 (83.3) 3 (100.0)
Israel (76) 2 (2.6) 7 (11.8) 39 (63.2) 27 (98.7) 1 (100.0)
Italy (299) 22 (7.4) 134 (52.2) 123 (93.3) 20 (100.0)
Poland (29) 16 (55.2) 13 (100.0)
Russia (7) 1 (14.3) 5 (85.7) 1 (100.0)
Spain (129) 1 (0.8) 9 (7.8) 83 (72.1) 35 (99.2) 1 (100.0)
Sweden (65) 6 (9.2) 35 (63.1) 20 (93.8) 4 (100.0)
Switzerland (107) 5 (4.7) 66 (66.4) 34 (98.1) 2 (100.0)
Turkey (171) 10 (5.8) 97 (62.6) 59 (97.1) 5 (100.0)
UK (62) 6 (9.7) 38 (71.0) 12 (90.3) 6 (100.0)
Total (1942) 39 (2.0) 120 (8.2) 1052 (62.4) 659 (96.3) 72 (100.0)
Enterococcus spp.
Belgium (48) 1 (2.1) 21 (45.8) 9 (64.6) 14 (93.8) 3 (100.0)
France (247) 2 (0.8) 11 (5.3) 104 (47.9) 87 (82.6) 25 (92.7) 18 (100.0)
Germany (353) 1 (0.3) 5 (1.7) 93 (28.0) 153 (71.4) 61 (88.7) 39 (99.7) 1 (100.0)
Greece (62) 2 (3.2) 23 (40.3) 17 (67.7) 16 (93.5) 4 (100.0)
Ireland (80) 17 (21.3) 29 (57.5) 30 (95.0) 4 (100.0)
Israel (39) 2 (5.1) 17 (48.7) 13 (82.1) 4 (92.3) 2 (97.4) 1 (100.0)
Italy (166) 1 (0.6) 4 (3.0) 7 (7.2) 39 (30.7) 63 (68.7) 37 (91.0) 15 (100.0)
Poland (32) 3 (9.4) 10 (40.6) 10 (71.9) 8 (96.9) 1 (100.0)
Russia (23) 1 (4.3) 7 (34.8) 8 (69.6) 5 (91.3) 2 (100.0)
Spain (144) 1 (0.7) 1 (1.4) 48 (34.7) 69 (82.6) 17 (94.4) 8 (100.0)
Sweden (131) 1 (0.8) 13 (10.7) 51 (49.6) 39 (79.4) 22 (96.2) 5 (100.0)
Switzerland (58) 2 (3.4) 24 (44.8) 17 (74.1) 13 (96.6) 2 (100.0)
Turkey (134) 1 (0.7) 2 (1.5) 6 (6.0) 46 (40.3) 25 (59.0) 21 (74.6) 34 (100.0)
UK (99) 1 (1.0) 5 (6.1) 46 (52.5) 28 (80.8) 10 (90.9) 9 (100.0)
Total (1616) 4 (0.2) 9 (0.8) 59 (4.5) 546 (38.2) 567 (73.3) 283 (90.8) 146 (99.9) 2 (100.0)
b-Haemolytic streptococci
Belgium (12) 4 (33.3) 4 (66.7) 4 (100.0)
France (169) 87 (51.5) 49 (80.5) 28 (97.0) 5 (100.0)
Germany (80) 34 (42.5) 27 (76.3) 19 (100.0)
Greece (3) 3 (100.0)
Ireland (18) 16 (88.9) 2 (100.0)
Israel (18) 10 (55.6) 5 (83.3) 2 (94.4) 1 (100.0)
Italy (16) 10 (62.5) 4 (87.5) 2 (100.0)
Poland (9) 7 (77.8) 1 (88.9) 1 (100.0)
Russia (34) 34 (100.0)
Spain (60) 44 (73.3) 7 (85.0) 8 (98.3) 1 (100.0)
Sweden (85) 41 (48.2) 18 (69.4) 21 (94.1) 5 (100.0)
Switzerland (31) 20 (64.5) 9 (93.5) 2 (100.0)
Turkey (7) 3 (42.9) 4 (100.0)
UK (118) 68 (57.6) 26 (79.7) 20 (96.6) 4 (100.0)
Total (660) 437 (66.2) 98 (81.1) 109 (97.6) 16 (100.0)
Viridans group streptococci
Belgium (22) 7 (31.8) 9 (72.7) 4 (90.9) 2 (100.0)
France (85) 12 (14.1) 26 (44.7) 19 (67.1) 20 (90.6) 7 (98.8) 1 (100.0)
Germany (45) 11 (24.4) 6 (37.8) 10 (60.0) 12 (86.7) 5 (97.8) 1 (100.0)
Greece (1) 1 (100.0)
Ireland (4) 2 (50.0) 1 (100.0)
Israel (13) 3 (23.1) 4 (53.8) 2 (69.2) 1 (100.0)
Italy (6) 1 (16.7) 3 (66.7) 2 (100.0)
Poland (2) 1 (50.0) 1 (100.0)
Russia (46) 1 (2.2) 38 (84.8) 7 (100.0)
Spain (22) 3 (13.6) 4 (31.8) 9 (72.7) 6 (100.0)
Sweden (48) 7 (14.6) 8 (31.3) 15 (62.5) 16 (95.8) 2 (100.0)
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The lowest antimicrobial susceptibility rates
were observed in Ireland, with 52.2% of entero-
coccal isolates being susceptible to ampicillin,
44.4% to gentamicin, 81.3% to teicoplanin, and
78.8% to vancomycin. Belgium, France, Germany,
Poland, Spain, Sweden, Switzerland (the only
country without a VRE isolate) and Turkey had
vancomycin susceptibility rates of >95% (Ta-
ble 2). Vancomycin resistance did not appear to
affect daptomycin activity adversely.
The potency of daptomycin against enterococci
did not vary significantly among the studied
countries. MIC90 values were 2 mg ⁄L in all
countries except Germany and Turkey, where
the daptomycin MIC90 was 4 mg ⁄L (Table 3). In
Turkey, only 74.6% of enterococcal isolates were
inhibited at daptomycin 2 mg ⁄L, compared with
88.7–96.6% in the other countries evaluated. One
linezolid-non-susceptible isolate of E. faecalis
(MIC 4 mg ⁄L) was isolated in France (Table 2),
while daptomycin-non-susceptible E. faecium iso-
lates were recovered in Germany (one isolate) and
Israel (one isolate) (Table 3).
b-Haemolytic streptococci
b-Haemolytic streptococci exhibited high rates of
susceptibility to most antimicrobial agents tested.
Decreased susceptibility was detected only to
tetracycline (51.5%), erythromycin (84.1%) and
clindamycin (94.2%) (Table 1). All b-haemolytic
streptococcal isolates were inhibited at daptomy-
cin £0.5 mg ⁄L, with 97.6% inhibited at
£0.25 mg ⁄L (the CLSI and US-FDA susceptible
breakpoint is £1 mg ⁄L).
There were no significant inter-country varia-
tions in the antimicrobial resistance patterns of
b-haemolytic streptococci, except for tetracycline
and erythromycin (Table 2). The lowest rates of
susceptibility to tetracycline were observed in
Belgium (25.0%, only 12 isolates) and Greece
(37.5%), while the highest rates were observed in
Spain (76.7%). Erythromycin susceptibility rates
varied from 50.0% in Italy to 100.0% in Belgium,
Greece and Switzerland (Table 2). This group of
organisms showed the narrowest daptomycin
MIC range (£0.06–0.5 mg ⁄L). Isolates from all
countries had a daptomycin MIC50 of £0.06 mg ⁄L
or 0.12 mg ⁄L, and an MIC90 of 0.12 mg ⁄L or
0.25 mg ⁄L (Table 3).
Viridans group streptococci
Vancomycin and linezolid were the compounds
most active against viridans group streptococci
(MIC90 1 mg ⁄L; 100% susceptible), followed by
daptomycin (MIC90 0.5 mg ⁄L; 99.1% susceptible),
clindamycin (MIC90 >8 mg ⁄L; 84.1% susceptible)
and levofloxacin (MIC90 1 mg ⁄L; 98.2% suscept-
ible). Overall, 72.9% of isolates were fully sus-
ceptible to penicillin (7.9% resistant), with
susceptibility rates varying from only 30.8% in
Turkey to 87.1% in the UK among countries from
which >20 isolates were tested (Table 2). Only
three isolates had an elevated, reproducible dap-
tomycin MIC of 2 mg ⁄L (one each from France,
Germany and the UK). The susceptibility patterns
by country of viridans group streptococci, as well
as country-to-country variation of daptomycin
potency, could not be evaluated adequately
because of limited numbers of isolates submitted
from invasive infections by some countries.
DISCUSSION
The emergence and dissemination of MRSA in
Europe is a concern because these isolates are
often resistant to multiple antimicrobial agents.
The overall MRSA rate in the present study was
26.7%, which is comparable to or slightly higher
than that reported in previous studies [1–3,19].
However, MRSA rates varied greatly among
countries, with Belgium, Greece, Ireland, Israel
and the UK displaying >40% resistance, while
Sweden showed only 0.6% resistance. Similar
geographical variations have been reported in
Table 3. Continued
Organism/country (no. tested)
No. of isolates (cumulative %) inhibited at MIC (mg/L):
£0.06 0.12 0.25 0.5 1 2 4 8
Switzerland (35) 6 (17.1) 7 (37.1) 9 (62.9) 8 (85.7) 5 (100.0)
Turkey (26) 1 (3.8) 3 (15.4) 5 (34.6) 12 (80.8) 5 (100.0)
UK (31) 3 (9.7) 6 (29.0) 10 (61.3) 10 (93.5) 1 (96.8) 1 (100.0)
Total (340) 47 (13.8) 72 (35.0) 94 (62.6) 96 (90.9) 28 (99.1) 3 (100.0)
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previous studies, and may reflect differences in
infection control policies and other factors
[4,20,21]. The emergence of MRSA is caused
largely by dissemination of clonal strains, and
hospital outbreaks are typically the result of cross-
transmission of these strains among patients.
However, a direct correlation between antimicro-
bial usage and resistance rates has been difficult
to establish because of the high number of
variables involved [21,22].
Vancomycin-resistant Staph. aureus is a serious
concern, but very few isolates have been reported
to date, all of which have been in the USA. In
addition, there are many reports of vancomycin-
intermediate Staph. aureus, and following the
reduction in the CLSI vancomycin-susceptible
breakpoint from 4 to 2 mg ⁄L [17], such reports
may become more frequent. In the present study,
only one Staph. aureus isolate with a vancomycin-
intermediate MIC value (4 mg ⁄L) was detected.
This isolate was oxacillin- and daptomycin-sus-
ceptible (MIC 0.5 mg ⁄L for both agents), and was
isolated from a patient with bloodstream infection
in Poland.
A further interesting finding of this study was
the detection of 20 Staph. aureus isolates with qui-
nupristin–dalfopristin MICs ‡2 mg ⁄L. Germany,
Italy and the UK each submitted one quinupristin–
dalfopristin-resistant isolate, while France submit-
ted 17 such isolates. Quinupristin–dalfopristin-
resistant Staph. aureus isolates have been reported
previously from France, and the emergence and
dissemination of this resistance phenotype may be
related to the clinical use of natural streptogramin
mixtures, e.g., pristiniamycin and synergistin,
orally and topically since the 1960s [23].
Although vancomycin resistance rates in Eur-
ope are relatively low compared with those
reported in the USA [19], VRE appear to have
become more prevalent in Europe in recent years,
with 21.0% of E. faecium isolates displaying resist-
ance in 2005 [24]. In the present study, overall
vancomycin resistance rates were relatively high
(>15.0%), with levels of 19.7% in Greece, 21.2% in
Ireland, 15.7% in Italy, 15.4% in Israel and 15.2%
in the UK. Interestingly, the highest MRSA rates
(>40.0%) were also observed in these five coun-
tries plus Belgium (Table 2), indicating that these
two resistance phenotypes may be related epi-
demiologically [21,22]. Furthermore, the results of
the present study confirmed previous reports by
showing that daptomycin is active against many
MDR Gram-positive strains, and that vancomycin
resistance does not significantly affect the in-vitro
activity of daptomycin [11].
In conclusion, daptomycin demonstrated excel-
lent in-vitro activity against recent clinical isolates
of Gram-positive bacteria (9322 isolates) collected
from 14 countries in Europe. As daptomycin
possesses a unique mechanism of action (i.e., it
targets the bacterial membrane in the presence of
calcium), it demonstrates no cross-resistance with
other classes of antimicrobial agent, making it an
excellent option for the treatment of infections
caused by MDR organisms [8,11,24–27]. Although
the in-vitro activities of daptomycin were very
consistent among the participating countries,
variations were apparent for other antimicrobial
agents.
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